CareStart Tests for State of Utah

The State of Utah's Division of Purchasing issued a Request for Quotes (RFQ) under solicitation MG21-12 for the urgent procurement of 500,000 CareStart COVID-19 Antigen tests, with potential for additional orders. The tests are lateral flow immunochromatographic assays designed for qualitative detection of SARS-CoV-2 nucleocapsid protein antigen from nasopharyngeal swab specimens. The procurement was driven by time-sensitive CARES funding expiration, with a delivery deadline of December 31, 2020. Quotes were to be submitted to christopherhughes@utah.gov by December 11, 2020, at 2:00 PM Mountain Standard Time. Vendor evaluation criteria included prior experience providing testing materials to the state, confirmation of licensing requirements, and certification that tests meet or exceed specified technical requirements. The state reserved the right to award to one or multiple vendors based on need and availability. Commodity codes associated with this procurement encompassed medical testing, healthcare services, and medical supplies.

No specific set-aside designations or restrictions on vendor types were explicitly mentioned in the documentation. The procurement appeared open to qualified medical supply vendors capable of meeting the technical specifications and delivery timeline. While the total potential award value was not precisely defined, the initial order was for 500,000 tests, with potential for additional purchases. The urgent nature of the procurement and the CARES funding context suggested a relatively high-value contract with immediate implementation needs. Vendors were required to provide comprehensive company information and demonstrate capability to quickly supply COVID-19 antigen testing materials. The state's approach indicated flexibility in vendor selection, prioritizing vendor responsiveness, test quality, and ability to meet the critical public health testing requirements during the pandemic response.